What Scintomics GmbH does

Scintomics GmbH is a privately held German radiopharmaceutical technology company founded in 2006 by Prof. Hans-Jürgen Wester, Chair of Pharmaceutical Radiochemistry at the Technical University of Munich. The company is headquartered in Gräfelfing near Munich and operates with 11-50 employees, focused on bridging preclinical radiochemistry research and clinical development of theranostic agents for oncology. Its technology portfolio centers on the proprietary Radiohybrid Technology platform — a class of radiopharmaceuticals carrying two labeling sites (one for fluorine, one for a metal isotope) that enables the same molecular construct to be labeled with PET imaging isotopes (18F, 68Ga) or therapeutic radionuclides (177Lu, 225Ac). Supporting platforms include On-Cartridge Drying (18F-labeling without azeotropic drying, enabling >100 GBq scale production in ~15 minutes under GMP), Silicon-Fluorine Acceptor (SiFA) isotopic exchange, and metabolic stabilization chemistry. The product portfolio spans rhPSMA (lead 18F-rhPSMA-7.3, approved by the FDA as POSLUMA in May 2023 via Blue Earth Diagnostics), siPSMA, rhTATE, rhCCK, PSMA I&T, PentixaFor/PentixaTher (CXCR4-targeted, now controlled by Eckert & Ziegler), and the GRP Module Series of GMP-compliant automated synthesizers.

Scintomics derives revenue through two distinct GTM motions. The first is a licensing and royalty model: the company has out-licensed rhPSMA imaging rights (Blue Earth Diagnostics, 2018) and therapeutic rights (Blue Earth, 2020/2021) as well as a portfolio of 70+ patented next-generation PSMA radioligands (POINT Biopharma, 2020), earning development milestones, regulatory milestone payments, and royalties on commercialization. The second is direct sales of fully automated GMP-compliant synthesis modules, cassettes, reagent sets, and proprietary/non-proprietary labeling precursors to nuclear medicine clinics and research facilities worldwide — historically via Scintomics ATT (Applied Theranostics Technologies), the subsidiary founded in 2018 and explicitly spun out in 2020 to take over the module, consumable, and precursor business while the parent refocused on clinical development.

The company has historically relied on technology inflow from TUM/BayPAT (rhPSMA, CXCR4 compounds, 18F-labeling, RGD peptides, adrenocortical tracers) and operates a small venture-backed subsidiary, PentixaPharm GmbH, formed as a 2019 joint venture with 1717 Life Science Ventures for CXCR4 development (closed a EUR 15M Series A in 2020; 83% acquired by Eckert & Ziegler in 2021 for ~EUR 30M). Scintomics received the 2019 TUM Presidential Entrepreneurship Award and maintains a global installed base of 150+ synthesis systems. Revenue figures are not publicly disclosed.

Name

Scintomics GmbH

Legal name

Scintomics GmbH

Website

https://scintomics.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Scintomics GmbH is a Munich-based radiopharmaceutical technology company founded in 2006 that develops and licenses Radiohybrid theranostic agents and GMP synthesis modules, serving nuclear medicine clinics and pharma licensing partners such as Blue Earth Diagnostics and POINT Biopharma.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Technology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)

akta.pro secondary industries

Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC), Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA), Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors) (HLAIAGAG)

Keywords

• Radiopharmaceutical technology
• Cancer diagnostic imaging
• Radioligand therapy
• PET imaging agents
• Automated radiopharmaceutical synthesizers

Headquarters

HQ city

Fürstenfeldbruck

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Technology Licensing - Blue Earth Diagnostics: Scintomics licenses its radiohybrid PSMA technology to Blue Earth Diagnostics. The company receives milestone payments and royalties from diagnostic and therapeutic applications. Blue Earth acquired exclusive worldwide rights to rhPSMA imaging technology in 2018 and therapeutic rights in 2020.
2. Technology Licensing - POINT Biopharma: Licensing agreement with POINT Biopharma for exclusive use and development of a family of more than seventy patented next generation PSMA radioligands for targeted radiotherapy. Scintomics is eligible to receive milestone payments and royalties over the life of the collaboration.
3. Synthesis Modules and Consumables: Sale of fully automated GMP-compliant synthesis modules and corresponding consumables for radiopharmaceutical production to nuclear medicine clinics and research facilities worldwide.
4. Radiopharmaceutical Precursors: Sale of proprietary and non-proprietary labeling precursors for radiopharmaceutical production through subsidiary Scintomics ATT (Applied Theranostics Technologies).

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Scintomics develops proprietary radiopharmaceutical technologies and a portfolio of theranostic compounds for cancer diagnosis and radioligand therapy, anchored by its Radiohybrid Technology platform. The company also manufactures and sells GRP Module Series automated synthesizers along with cassettes, reagent sets, and labeling precursors for GMP-compliant radiopharmaceutical production, primarily through licensing partnerships with pharmaceutical companies and direct sales to nuclear medicine facilities worldwide.

Product overview

Scintomics GmbH is a radiopharmaceutical technology company offering a portfolio of innovative tracer technologies for molecular imaging and radioligand therapy in oncology. The core offering includes the Radiohybrid Technology Platform, which enables dual labeling for both diagnostic imaging (18F, 68Ga) and therapeutic applications (177Lu, 225Ac). The product portfolio spans prostate cancer candidates (rhPSMA, siPSMA, PSMA PNT2002), neuroendocrine tumor candidates (rhTATE), and CXCR4-targeted theranostics (PentixaFor/PentixaTher). Supporting technologies include On-Cartridge Drying, Isotopic Exchange, and Metabolic Stabilization technologies. The company also manufactures GRP Module Series automated synthesizers for GMP radiopharmaceutical production. Products are developed through subsidiaries, joint ventures (PentixaPharm), and licensing partnerships (Blue Earth Diagnostics, POINT Biopharma).

Differentiator

Problem solved

Functional benefit

Products and services

• GRP Module Series Fully automated GMP-compliant synthesis modules with tailor-made synthesis cassettes and reagent sets for the production of radiopharmaceuticals, sold to nuclear medicine clinics and research facilities.
• PentixaFor 68Ga-based PET imaging agent targeting the CXCR4 receptor for visualization of hematologic malignancies (leukemia, lymphoma, multiple myeloma), solid tumors (adrenocortical carcinoma, small cell lung cancer), and other conditions including atherosclerosis and stroke.
• PentixaTher CXCR4-targeted endoradiotherapy agent labeled with alpha or beta emitters, designed as the therapeutic counterpart to PentixaFor for individualized treatment of CXCR4-expressing malignancies.
• rhPSMA (Radiohybrid PSMA) Radiohybrid Prostate-Specific Membrane Antigen-targeted compound for prostate cancer imaging (F-18) and therapy (Lu-177, Ac-225), licensed worldwide to Blue Earth Diagnostics.
• PSMA I&T

Quantifiable outcome

• Over 150 synthesis modules installed globally, building extensive network of medical and scientific collaborations
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Seven partnerships are on record, tiered core.

• Blue Earth DiagnosticscoreStrategic or Co-development Partner · 5 January 2021Blue Earth Diagnostics, a Bracco company, acquired exclusive worldwide rights to therapeutic applications of Scintomics' radiohybrid PSMA technology. Blue Earth previously acquired diagnostic rights in 2018 and now holds comprehensive rights for both imaging and therapeutic applications. The partnership includes collaboration with Technical University of Munich to identify optimized therapeutic candidates.
• POINT BiopharmacoreStrategic or Co-development Partner · 10 March 2020POINT Biopharma acquired exclusive rights to a family of more than seventy patented next generation PSMA radioligands for targeted radiotherapy of prostate cancer. Scintomics received milestone payments and royalties over the life of the collaboration.
• 1717 Life Science Ventures GmbHcoreStrategic or Co-development Partner · 15 May 2019Joint venture partnership to form PentixaPharm GmbH for development of CXCR4-targeted theranostics. Scintomics and 1717 LSV collaborated to develop PentixaFor and PentixaTher as a theranostic pair targeting the CXCR4-receptor.
• Blue Earth DiagnosticscoreStrategic or Co-development Partner · 2 May 2018Initial licensing agreement where Blue Earth Diagnostics acquired exclusive worldwide rights to rhPSMA imaging technology. This agreement included an exclusive option to explore therapeutic applications, which was later exercised in 2020.
• Technical University of Munich (TUM)coreTechnology or IntegrationTechnology origin and research partnership. Radiohybrid technology and rhPSMA originated from Prof. Hans-Jürgen Wester's group at TUM's Institute for Pharmaceutical Chemistry. Scintomics licenses technologies from TUM through BayPAT technology transfer office.
• BayPAT (Bayerische Patentallianz)coreTechnology or IntegrationBavarian technology transfer office that commercializes innovations from 33 research institutes. BayPAT out-licensed multiple technologies to Scintomics including rhPSMA, CXCR4 compounds, 18F-labeling technology, and others.
• Scintomics ATT (Applied Theranostics Technologies)coreStrategic or Co-development PartnerSubsidiary founded in 2018 that continues the Automation & Precursor business segment. Handles sale of proprietary and non-proprietary labeling precursors and distribution of fully automated synthesizers and consumables.

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Novartis (Radioligand Therapy): Acquired Endocyte and AAA to build a radioligand therapy franchise led by Pluvicto (177Lu-PSMA-617) and Lutathera. The dominant commercial player in PSMA-targeted radiotherapy whose market position Scintomics-licensed assets must compete against via sublicensees.
• Curium Pharma: Global nuclear medicine company producing diagnostic and therapeutic radiopharmaceuticals across SPECT, PET, and emerging therapy indications. Comparable as both a supplier of radiopharmaceuticals and a competitor licensing/manufacturing in the same space.
• Lantheus Holdings: Established radiopharmaceutical company with a broad portfolio including PSMA imaging (Pylarify) and radioligand therapy assets following the AAA acquisition. Overlaps with Scintomics in PSMA imaging and the broader theranostic space, but operates at much larger scale.
• Bayer (Radiopharmaceuticals / Telix competitor): Sold legacy radiopharma assets (Xofigo/radium-223) and retains broader pharma interest in targeted radionuclide therapy. Comparable as an incumbent investor and developer in prostate-cancer radiopharmaceuticals, though its direct presence in PSMA is more limited than Novartis or Telix.

Emerging players

• Blue Earth Diagnostics: Bracco subsidiary that has acquired all Scintomics' rhPSMA imaging and therapeutic rights and brought POSLUMA through FDA approval. Operates in overlapping indication space (PSMA imaging/therapy) and effectively functions as Scintomics' commercialization partner for rhPSMA.
• POINT Biopharma: Radiopharmaceutical company developing PSMA-targeted radiotherapy using a Scintomics-licensed library of 70+ next-generation radioligands (PNT2002 program). Direct overlap in mechanism and indication space; functions as a partner for Scintomics while remaining a commercial-stage competitor.

Direct peers

• ITM Isotope Technologies Munich: Munich-based radiopharmaceutical manufacturer developing targeted radionuclide therapies (including PSMA and Lu-177 candidates). Direct competitor in theranostic radioligand development and GMP manufacturing, based in the same German ecosystem.
• ABX Advanced Biochemical Compounds: German manufacturer of radiopharmaceutical precursors, reference standards, and synthesis consumables. Comparable business in supplying cold kits, precursors, and synthesis inputs to nuclear medicine pharmacies — overlapping with Scintomics ATT's precursor and consumables business.
• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company with FDA-approved PSMA imaging agent Illuccix and a pipeline of therapeutic radioligands. Directly comparable in PSMA theranostic franchise and is the most prominent incumbent in the same indication Scintomics serves via Blue Earth/POINT.
• Eckert & Ziegler Strahlen- und Medizintechnik AG: German radiopharma and isotope specialist that acquired an 83% stake in PentixaPharm in 2021. Directly comparable as a manufacturer of radiopharmaceutical isotopes, synthesis modules, and CXCR4 theranostics through its PentixaPharm subsidiary.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scintomics GmbH